Dissertation > Excellent graduate degree dissertation topics show

Comparative Study of Intermittent Versus Continuous Androgen Blockade in the Treatment of Advanced Prostate Cancer

Author: ChenJianZuo
Tutor: ZhuShaoXing
School: Fujian Medical
Course: Surgery
Keywords: Prostate tumors Intermittent androgen blockade Persistent androgen blockade Quality of Life Side effect
CLC: R737.25
Type: Master's thesis
Year: 2008
Downloads: 82
Quote: 0
Read: Download Dissertation

Abstract

Objective: To compare intermittent androgen blocking persistent androgen deprivation therapy for advanced prostate cancer, the efficacy and side effects. : Select advanced prostate cancer, 44 cases were divided into two groups. The experimental group (IAD group) 21 cases of intermittent androgen deprivation therapy (luteinizing hormone releasing hormone analogue anti-androgen drugs), control group (CAD group) 23 cases of persistent androgen deprivation therapy (surgery to potential anti-androgen drugs). Through regular observation of the patient's serum prostate-specific antigen, testosterone levels and clinical symptoms, and quality of life scale EORTC QLQ-PR25 get their quality of life data, so as to compare the two groups of patients with prostate cancer progression, quality of life and adverse occurrence. Results: 1 prostate cancer progression: IAD patients a mean follow-up of 24 (10 to 39) months, CAD patients followed up for an average of 22 (9 to 36) months. IAD group of patients with a median time to progression of 36 months, the median time to progression of CAD patients for 30 months, progression-free survival was no significant difference between the two groups (p = 0.132). 2 the IAD treatment cycles of: the IAD group of patients, the average treatment cycle was 15.9 months, 9.1 months in which the treatment period, the interim period of 7.6 months. With the repetition of the treatment cycle, the gradual increase in the proportion of patients with disease progression, the intermittent period gradually shortened. 3, the patient's quality of life and the occurrence of adverse circumstances: in the intermittent period, the the IAD group of patients with treatment-related symptoms improved (P = 0.007); bone pain, urinary symptoms and bowel symptoms had no significant (P gt. ; 0.05). CAD patients to continue after 5 months of treatment, increased urinary tract symptoms (P = 0.023), bone pain, bowel symptoms, and treatment-related symptoms was no significant change (P gt; 0.05). Hot flashes in the IAD group the rate was 28.6% (6/21), the CAD group was 60.9% (14/23). Breast tenderness in the incidence rate of the IAD group, 19.0% (4/21), the CAD group was 52.2% (12/23). The two sets of hot flashes, there are significant differences in the incidence of breast tenderness (P lt; 0.05). The IAD group of patients with intermittent hot flashes, breast tenderness than the treatment period were improved (P lt; 0.05). CAD patients treatment five months after the hot flashes, breast tenderness than before, no significant improvement (P gt; 0.05). Conclusion: Intermittent androgen deprivation therapy safe and feasible. It can reduce the side effects caused by androgen blockade, and slow the progress of prostate cancer at least equivalent to continuous androgen deprivation therapy. Therefore, intermittent androgen blockade endocrine treatment of advanced prostate cancer patients may be a better way.

Related Dissertations

CLC: > Medicine, health > Oncology > Genitourinary tumors > Male genitalia tumors > Prostate cancer
© 2012 www.DissertationTopic.Net Mobile